65 results
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
6 Dec 23
Regulation FD Disclosure
7:05am
patients non-evaluable 2 recently enrolled and have not reached the initial response assessment as of the November 13, 2023 data cut-off 1 patient … discontinued during cycle 1 (prior to starting tamibarotene) without a response assessment 1 Ven/Aza patient non-evaluable Discontinued study treatment
UPLOAD
SYRS
Syros Pharmaceuticals Inc.
15 Aug 18
Letter from SEC
12:00am
Reporting, page 139
1. You disclose that you have not included a report of management's
assessment regarding
internal control over financial … accounting firm,
you are required to
include a report of management's assessment regarding internal control
over financial
Joseph J. Ferra, Jr.
Syros
8-K
EX-10.1
SYRS
Syros Pharmaceuticals Inc.
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm
of all investigation, assessment, and remediation plans and reports prepared by or on behalf of Tenant in response to any such regulatory order … to Hazardous Substances. For purposes of this Lease, “Environmental Assessment” means an assessment including, without limitation: (i) an environmental
8-K
EX-99.1
zj0jfkr8nqz2xlq
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
EX-99.2
z532r05927 6fxfn
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.2
p9iobqmjmv6mfbyn
15 Nov 18
Regulation FD Disclosure
4:03pm
8-K
EX-99.1
rsynrd709cz4w3fr
15 Nov 18
Regulation FD Disclosure
4:03pm